Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)

Authors

  • O. P. Kolesnik Zaporizhzhia State Medical University, Ukraine, Ukraine
  • V. V. Mykhailychenko Zaporizhzhia State Medical University, Ukraine, Ukraine

DOI:

https://doi.org/10.14739/2310-1210.2021.3.216471

Keywords:

non-small cell lung cancer, immune checkpoint inhibitors, treatment

Abstract

Aim. Based on scientific literature data, to evaluate the effectiveness of the use of immune checkpoint inhibitors (ICI) in the treatment of non-small cell lung cancer (NSCLC).

Materials and methods. To analyze the results of clinical trials of NSCLC treatment with immune checkpoint inhibitors.

Conclusions. Among the immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, namely Nivolumab, Pembrolizumab and Atezolizumab, are most successful in the treatment of NSCLC. Their use significantly increases overall survival and progression-free survival with a lower profile of adverse events. They are prescribed as both second-line and first-line drugs in the NSCLC therapy. Such biomarkers as Teff gene expression level, tumor mutational load (TMB) level and interferon gamma (IFNG) mRNA expression level have also been identified. They allow to more accurately determine the group of patients who will show the best response to therapy with PD-1/ PD-L1 inhibitors.

Author Biographies

O. P. Kolesnik, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Oncology and Oncosurgery

V. V. Mykhailychenko, Zaporizhzhia State Medical University, Ukraine

Student

References

Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016). Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 34, 539-573. https://doi.org/10.1146/annurev-immunol-032414-112049

Bogolyubova, A. V., Efimov, G. A., Drutskaya, M. S., & Nedospasov, S. A. (2015). Immunoterapiya opukholei, osnovannaya na blokirovke immunologicheskikh kontrol'nykh «tochek» («chekpointov») [Cancer immunotherapy based on the blockade of immune checkpoints]. Meditsinskaya immunologiya, 17(5), 395-406. https://doi.org/10.15789/1563-0625-2015-5-395-406 [in Russian].

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., … Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373(17), 1627-1639. https://doi.org/10.1056/NEJMoa1507643

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., … Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373(2), 123-135. https://doi.org/10.1056/NEJMoa1504627

Burr, M. L., Sparbier, C. E., Chan, Y. C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E., Henderson, M. A., Bell, C. C., Stolzenburg, S., Gilan, O., Bloor, S., Noori, T., Morgens, D. W., Bassik, M. C., Neeson, P. J., Behren, A., Darcy, P. K., Dawson, S. J., Voskoboinik, I., … Dawson, M. A. (2017). CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 549(7670), 101-105. https://doi.org/10.1038/nature23643

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T. E., Badin, F., Ready, N., Hiltermann, T., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R., Jr., … CheckMate 026 Investigators. (2017). First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376(25), 2415-2426. https://doi.org/10.1056/NEJMoa1613493

de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. Translational Lung Cancer Research, 7(3), 220-233. https://doi.org/10.21037/tlcr.2018.05.06

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., Rubio-Viqueira, B., … KEYNOTE-189 Investigators. (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378(22), 2078-2092. https://doi.org/10.1056/NEJMoa1801005

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M. J., Felip, E., Lee, J. S., Hellmann, M. D., Hamid, O., Goldman, J. W., Soria, J. C., Dolled-Filhart, M., Rutledge, R. Z., … KEYNOTE-001 Investigators. (2015). Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. The New England Journal of Medicine, 372(21), 2018-2028. https://doi.org/10.1056/NEJMoa1501824

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., Leming, P., Geese, W. J., Yoon, D., Li, A., & Brahmer, J. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology, 36(17), 1675-1684. https://doi.org/10.1200/JCO.2017.77.0412

Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O'Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., … Paz-Ares, L. (2018). Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England Journal of Medicine, 378(22), 2093-2104. https://doi.org/10.1056/NEJMoa1801946

Hendriks, L., Henon, C., Auclin, E., Mezquita, L., Ferrara, R., Audigier-Valette, C., Mazieres, J., Lefebvre, C., Rabeau, A., Le Moulec, S., Cousin, S., Duchemann, B., le Pechoux, C., Botticella, A., Ammari, S., Gazzah, A., Caramella, C., Adam, J., Lechapt, E., Planchard, D., … Besse, B. (2019). Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Journal of Thoracic Oncology, 14(7), 1244-1254. https://doi.org/10.1016/j.jtho.2019.02.009

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., Majem, M., Fidler, M. J., de Castro, G., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M., & Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, 387(10027), 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO journal, 11(11), 3887-3895.

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., Algarra, S. M., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R. (2018). Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 10, 1-23. https://doi.org/10.1177/1758834017749748

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M., Slagter, M., Rozeman, E. A., Hofland, I., Broeks, A., Horlings, H. M., Wessels, L., Blank, C. U., Xiao, Y., Heck, A., Borst, J., Brummelkamp, T. R., & Schumacher, T. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 549(7670), 106-110. https://doi.org/10.1038/nature23669

Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., Lopes, G., & KEYNOTE-042 Investigators. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet, 393(10183), 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264. https://doi.org/10.1038/nrc3239

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., … KEYNOTE-407 Investigators. (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379(21), 2040-2051. https://doi.org/10.1056/NEJMoa1810865

Quezada, S. A., & Peggs, K. S. (2013). Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. British Journal of Cancer, 108(8), 1560-1565. https://doi.org/10.1038/bjc.2013.117

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., Brahmer, J. R., & KEYNOTE-024 Investigators. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375(19), 1823-1833. https://doi.org/10.1056/NEJMoa1606774

Remon, J., Hendriks, L., Aspeslagh, S., & Besse, B. (2019). Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases? Journal of Thoracic Oncology, 14(10), 1701-1703. https://doi.org/10.1016/j.jtho.2019.07.004

Remon, J., Vilariño, N., & Reguart, N. (2018). Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treatment Reviews, 64, 21-29. https://doi.org/10.1016/j.ctrv.2018.02.002

Ribas, A. (2015). Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discovery, 5(9), 915-919. https://doi.org/10.1158/2159-8290.CD-15-0563

Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355. https://doi.org/10.1126/science.aar4060

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J.-S., & Ballinger, M. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, 389(10066), 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X

Sacher, A. G., & Gandhi, L. (2016). Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. JAMA Oncology, 2(9), 1217-1222. https://doi.org/10.1001/jamaoncol.2016.0639

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7-30. https://doi.org/10.3322/caac.21442

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., Reck, M., … IMpower150 Study Group. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. The New England Journal of Medicine, 378(24), 2288-2301. https://doi.org/10.1056/NEJMoa1716948

Sznol, M., Powderly, J. D., Smith, D. C., Brahmer, J. R., Drake, C. G., McDermott, D. F., Lawrence, D. P., Wolchok, J. D., Topalian, S. L., & Lowy, I. (2010). Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. Journal of Clinical Oncology, 28(15), 2506-2506. https://doi.org/10.1200/jco.2010.28.15_suppl.2506

Torre, L. A., Siegel, R. L., & Jemal, A. (2016). Lung Cancer Statistics. In A. Ahmad & S. Gadgeel (Eds.), Lung Cancer and Personalized Medicine. Advances in Experimental Medicine and Biology (Vol. 893, pp. 1-19). Springer, Cham. https://doi.org/10.1007/978-3-319-24223-1_1

Uldrick, T. S., Gonçalves, P. H., Abdul-Hay, M., Claeys, A. J., Emu, B., Ernstoff, M. S., Fling, S. P., Fong, L., Kaiser, J. C., Lacroix, A. M., Lee, S. Y., Lundgren, L. M., Lurain, K., Parsons, C. H., Peeramsetti, S., Ramaswami, R., Sharon, E., Sznol, M., Wang, C. J., Yarchoan, R., … Cancer Immunotherapy Trials Network (CITN)-12 Study Team. (2019). Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer - A Phase 1 Study. JAMA Oncology, 5(9), 1332-1339. https://doi.org/10.1001/jamaoncol.2019.2244

Ventola, C. L. (2017). Cancer Immunotherapy, Part 1: Current Strategies and Agents. P & T, 42(6), 375-383.

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H., Signori, E., Honoki, K., Georgakilas, A. G., Amin, A., Helferich, W. G., Boosani, C. S., Guha, G., Ciriolo, M. R., Chen, S., Mohammed, S. I., … Kwon, B. S. (2015). Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 35, S185-S198. https://doi.org/10.1016/j.semcancer.2015.03.004

Published

2021-06-07

How to Cite

1.
Kolesnik OP, Mykhailychenko VV. Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review). Zaporozhye Medical Journal [Internet]. 2021Jun.7 [cited 2024Nov.2];23(3):417-24. Available from: http://zmj.zsmu.edu.ua/article/view/216471

Issue

Section

Review